Clinical Trials Logo

Severe Malaria clinical trials

View clinical trials related to Severe Malaria.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06064591 Recruiting - Severe Malaria Clinical Trials

Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX

IMMETASEX
Start date: December 13, 2023
Phase:
Study type: Observational [Patient Registry]

Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. A new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion rates in natural infections.

NCT ID: NCT05711485 Recruiting - Thrombocytopenia Clinical Trials

Platelet-Directed Whole Blood Transfusion Strategy for Malaria

PLATFORM
Start date: February 24, 2024
Phase: N/A
Study type: Interventional

Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.

NCT ID: NCT05685875 Recruiting - Obesity Clinical Trials

Association of Diabetes and Metabolic Syndrome With Severe Malaria in Cameroon

Start date: June 7, 2022
Phase:
Study type: Observational

The aim of this study is to investigate if diabetes, obesity and metabolic syndrome affects disease presentation and severity of malaria in adults in a hospital setting in Cameroon.

NCT ID: NCT04675931 Recruiting - Severe Malaria Clinical Trials

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

Start date: March 7, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria. The study also intends to evaluate clinical treatment success using a novel clinical endpoint for drug development in severe malaria. Severe malaria is a medical emergency and is affecting primarily young children in Africa. Injectable artesunate is the standard of care for the treatment of severe malaria and is highly efficacious. However, the spread of artemisinin-resistance in Plasmodium falciparum in Asian countries poses a threat for future treatment of patients with this life-threatening disease. To mitigate this risk, there is a need of another drug in malaria endemic countries. Cipargamin treatment results in rapid clearance of parasites including artemisinin resistant parasites.

NCT ID: NCT04251351 Recruiting - Acute Kidney Injury Clinical Trials

Effect of Paracetamol on Kidney Function in Severe Malaria

PROTECtS
Start date: December 13, 2021
Phase: Phase 3
Study type: Interventional

A randomised open labeled, parallel-group, controlled trial to assess the efficacy of paracetamol to reduce kidney dysfunction caused by cell-free haemoglobin-mediated oxidative damage in paediatric patients with falciparum malaria complicated by intravascular haemolysis.